Asthmatic Patients Have an Increased Risk of Hyperthyroidism

xlomafota13 shared this article with you from Inoreader Asthmatic Patients Have an Increased Risk of Hyperthyroidism Via Clinical Thyroidology Clinical Thyroidology, Volume 33, Issue 12, Page 523-525, December 2021. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes

xlomafota13 shared this article with you from Inoreader Impact of modern personalized treatment of breast cancer on surgical attitude and outcomes Via Experimental and therapeutic medicine Exp Ther Med. 2022 Jan;23(1):57. doi: 10.3892/etm.2021.10979. Epub 2021 Nov 17. ABSTRACT Multimodal treatment of breast cancer has made steady progress in recent years. The involvement of modern oncology, diagnostic imaging techniques and surgical treatment, have brought a definite benefit to patients, defining the multidisciplinary treatment of breast cancer. The introduction of immunohistochemical testing and genetic screening has led to the prioritization of therapy according to their results and a correct approach to initiating treatment. The main aim of the present study was to conduct a comparative analysis through a retrospective study of the therapeutic means used in breast cancer with the statistical evaluation of the obtained results. To carry out the study, a group of 125 patients hospitalized during the period January 2015 to December 2020, were included, and the parameters were selected from the observation sheets. The res ults of the study demonstrated the superiority of multimodal treatment of breast cancer over surgical treatment as the only therapeutic management. The introduction of ultrasound-guided biopsies and conservative surgical options has led to increased diagnostic accuracy and a significant improvement in aesthetic outcome. The multidisciplinary approach to breast cancer allows an individualized treatment by performing immunohistochemical testing and through the use of neoadjuvant and adjuvant treatment combined with conservative surgical techniques with a more favorable cosmetic and oncological result, with reduced postoperative complications. PMID:34917183 | PMC:PMC8630438 | DOI:10.3892/etm.2021.10979 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

ASA Physical Status Classification and Complications Following Facial Fracture Repair

xlomafota13 shared this article with you from Inoreader ASA Physical Status Classification and Complications Following Facial Fracture Repair Via otol rhinol Ann Otol Rhinol Laryngol. 2021 Dec 17:34894211059599. doi: 10.1177/00034894211059599. Online ahead of print. ABSTRACT BACKGROUND: To investigate the association between American Society of Anesthesiologists (ASA) physical status classification and rates of postoperative complications in patients undergoing facial fracture repair. METHODS: Patients were divided into 2 cohorts based on the ASA classification system: Class I/II and Class III/IV. Chi-square and Fisher's ex act tests were used for univariate analyses. Multivariate logistic regressions were used to assess the independent associations of covariates on postoperative complication rates. RESULTS: A total of 3575 patients who underwent facial fracture repair with known ASA classification were identified. Class III/IV patients had higher rates of deep surgical site infection (P = .012) as well as bleeding, readmission, reoperation, surgical, medical, and overall postoperative complications (P < .001). Multivariate regression analysis found that Class III/IV was significantly associated with increased length of stay (P < .001) and risk of overall complications (P = .032). Specifically, ASA Class III/IV was associated with increased rates of deep surgical site infection (P = .049), postoperative bleeding (P = .036), and failure to wean off ventilator (P = .027). CONCLUSIONS: Higher ASA class is associated with increased length o f hospital stay and odds of deep surgical site infection, bleeding, and failure to wean off of ventilator following facial fracture repair. Surgeons should be aware of the increased risk for postoperative complications when performing facial fracture repair in patients with high ASA classification. PMID:34918565 | DOI:10.1177/00034894211059599 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Impact of the Mutational Landscape of the Sodium/Iodide Symporter in Congenital Hypothyroidism

xlomafota13 shared this article with you from Inoreader Impact of the Mutational Landscape of the Sodium/Iodide Symporter in Congenital Hypothyroidism Via liebertpub1 Thyroid, Volume 31, Issue 12, Page 1776-1785, December 2021. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model

xlomafota13 shared this article with you from Inoreader Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model Via liebertpub1 Thyroid, Volume 31, Issue 12, Page 1839-1849, December 2021. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway

xlomafota13 shared this article with you from Inoreader Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway Via histochem Acta Histochem. 2021 Dec 14;124(1):151811. doi: 10.1016/j.acthis.2021.151811. Online ahead of print. ABSTRACT Inflammatory bowel disease (IBD) impacts patient quality of life significantly. The dysfunction of intestinal immune barrier is closely associated with IBD. The guanylate cyclase-C (GC-C) signaling pathway activated by the guanylin (Gn) ligand is involved in the occurrence and development of IBD. However, how it regulates the intestinal immune barrier is still unclea r. To investigate the effect of the GC-C pathway on intestinal mucosal immunity and provide experimental basis for seeking new therapeutic strategies for IBD, we focused on Caco-2 cells and intestinal intra-epithelial lymphocytes (IELs), which displayed inflammatory responses induced by lipopolysaccharide (LPS). GC-C activity was modulated by transfection with Gn overexpression or GC-C shRNA plasmid. Levels of Gn, GC-C, and CFTR; transepithelial electrical resistance (TER); paracellula r permeability; and levels of IL-2, IFN-γ, and secretory IgA (sIgA) were examined. The study found that after stimulation with LPS, Gn, GC-C, CFTR, TER, and sIgA levels were all significantly reduced, IL-2 and IFN-γ levels as well as paracellular permeability were significantly increased. These indicators changed inversely and significantly after transfection with the Gn overexpression vector. Compared to the vector controls, GC-C-silenced cells displayed significantly decreased levels of GC-C, CFTR , and TER and increased levels of IL-2, IFN-γ, and paracellular permeability stimulated by LPS. The results show that Gn ligand can protect the intestinal immune barrier by activating the GC-C signaling pathway, which may be helpful for the development of new treatments for IBD. DATA AVAILABILITY STATEMENT: The data used to support the findings of this study are available from the corresponding author upon request. PMID:34920371 | DOI:10.1016/j.acthis.2021.151811 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Bispecific antibodies targeting CD3 in oncology and hematology

xlomafota13 shared this article with you from Inoreader Bispecific antibodies targeting CD3 in oncology and hematology Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S181-S194. doi: 10.1016/j.bulcan.2021.06.003. ABSTRACT Bispecific therapies targeting CD3, so-called T-cell engagers (TCE), belong to the new spectrum of anti-tumor immunotherapies stimulating T-lymphocytes. TCE are unique constructs targeting the MHC-independent CD3 epsilon subunit (CD3e) and a tumor antigen. To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19. Other TCE are in advances development, with promising results targeting CD20 and BSMA in lymphoma and myeloma. These successes have relaunched the development of TCE in solid tumors, bringing mixed results so far (notably in terms of tolerance). Still, TCE pave the way to new immunotherapy in tumors considered to be refractory to inhibitors of immune checkpoints such as prostate cancer or colorectal cancer. PMID:34920802 | DOI:10.1016/j.bulcan.2021.06.003 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Bispecific antibodies in onco-hematology: Applications and perspectives

xlomafota13 shared this article with you from Inoreader Bispecific antibodies in onco-hematology: Applications and perspectives Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S195-S204. doi: 10.1016/j.bulcan.2021.10.002. ABSTRACT Bispecific antibodies are novel approaches of immunotherapy engaging immune cells to destroy tumor cells. Their structure is variable and underlies their pharmacocinetic properties. These coumpounds are now being evaluated across multiple hematological malignancies. The anti-CD3/CD19 antibody blinatumomab is the first in class and have been approved for the treatment of patients with Ph-negative B-cell acute lymphoblastic leukemia. Other emerging applications are lymphoma, multiple myeloma and acute myeloid leukemia. The safety profile of bispecific antibodies is acceptable while limited by neurotoxicity and cytokine-release syndrome. The present review aims to depict the landscape of emerging bispecific antibodies currently in development for hematological malignancies. PMID:34920803 | DOI:10.1016/j.bulcan.2021.10.002 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

CAR-T cells in lymphomas: Current and evolving role

xlomafota13 shared this article with you from Inoreader CAR-T cells in lymphomas: Current and evolving role Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S28-S39. doi: 10.1016/j.bulcan.2021.04.022. ABSTRACT Three CD19 CAR-T cells (Yescarta®, Kymriah® and Breyanzi®), have been approved in relapsed or refractory diffuse large B cell lymphomas (DLBCL) after at least two previous lines of therapy. These immunotherapies have transformed the prognosis of these lymphomas, which can't be cured by conventional treatments. Long-term updates of registration studies as well as the first real-life data allow a better knowledge of the efficacy of these emerging therapies, their toxicity and their resistance mechanisms. These advances have also led to consider the earlier use of CAR-T cells in the therapeutic strategy and to extend it to other B lymphomas such as mantle cell and indolent lymphomas. Indeed, Yescarta® and Tecartus® have been recently approved in those malignancies, Furthermore, other strategies are being investigated to develop new CAR-T cells to targ et Hodgkin's lymphomas and T-cell lymphomas, although data in these settings still have to be completed. In this article, we review the latest data on the use of CAR-T cells in lymphomas. PMID:34920805 | DOI:10.1016/j.bulcan.2021.04.022 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

CAR-T cells, from principle to clinical applications

xlomafota13 shared this article with you from Inoreader CAR-T cells, from principle to clinical applications Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S4-S17. doi: 10.1016/j.bulcan.2021.02.017. ABSTRACT Chimeric antigen receptors (CAR)-T cells are genetically engineered T-lymphocytes redirected with a predefined specificity to any target antigen, in a non-HLA restricted manner, therefore combining antibody-type specificity with effector T-cell function. This strategy was developed some thirty years ago, after extensive work established the key role of the immune system against cancer. The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first clinical application of CAR-T cell was done in Rotterdam in 2005 for metastatic renal cell carcinoma and simultaneously at the National Cancer Institute (NCI) for metastatic ovarian cancer. These pioneered studie s failed to demonstrate a therapeutic benefit, but warning emerged concerning their safety of use. The real clinical success came with anti-CD19 CAR-T cells, used since 2009 by Steven Rosenberg at the NCI in a patient with refractory follicular lymphoma and in 2011 by Carl June and David Porter from the University of Pennsylvania in patients with chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. From that time, large centers in North America have embarked in several early phase and pivotal trials that have demonstrated unprecedent response rate in heavily pretreated chemo refractory patient with B-cell malignancies. Theses clinical success have led to the approval of three anti-CD19 CAR-T cells products for the management of B-cell malignancies in the United States and in Europe as of December 2020. PMID:34920806 | DOI:10.1016/j.bulcan.2021.02.017 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

CAR T-cells in acute lymphoblastic leukemia: Current results

xlomafota13 shared this article with you from Inoreader CAR T-cells in acute lymphoblastic leukemia: Current results Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct;108(10S):S40-S54. doi: 10.1016/j.bulcan.2021.08.001. ABSTRACT The marketing authorization of tisagenlecleucel, a 2nd generation of CD19-directed CAR T-cells, containing the 4-1 BB co-stimulatory domain, in 2017 in USA and in 2018 in EU, has revolutionized the therapeutic strategy in advanced B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents and young adults (AYAs) with relapsed or refractory disease. This innovative treatment, based on a "living drug", has shown very impressive short-term responses. However, safety profile and complex logistics require high expertise centers and tight collaborations between addressing and treating centers. Current research is exploring the possibility to move to first line ALL with high-risk features and/or first high-risk relapse. More efficient CAR T-cells products, are still lacking to counteract the escape mechanisms already described. Moreover, to define th e bridge-to-CAR time for each patient remains a challenge to obtain optimal disease burden allowing expansion and persistence of CAR T-cells. Also difficult is to identify patients who will benefit from further therapy after infusion, such as allogeneic HSCT or may be immuno-modulatory treatment. Finally, CAR T-cells directed against T-ALL are only in their beginning but require more complex engineering process to avoid T- cell immune-deficiency or fratricide. PMID:34920807 | DOI:10.1016/j.bulcan.2021.08.001 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.